IA
SRPT icon

IndexIQ Advisors’s Sarepta Therapeutics SRPT Stock Holding History

IndexIQ Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$61K Buy
+784
New +$60K ﹤0.01% 1126

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IndexIQ Advisors's SRPT Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q1 2022: 784 shares worth $61K. The stake represents ﹤0.01% of the portfolio and ranks #1126 among its holdings.

328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • IndexIQ Advisors held 784 shares of Sarepta Therapeutics worth $61K as of Q1 2022.
  • Sarepta Therapeutics was a new IndexIQ Advisors position in Q1 2022.
  • Sarepta Therapeutics made up ﹤0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #1126 holding.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.